Georgia Martimianaki1,2, Paola Bertuccio3, Gianfranco Alicandro4, Claudio Pelucchi1, Francesca Bravi1, Greta Carioli1, Rossella Bonzi1, Charles S Rabkin5, Linda M Liao5, Rashmi Sinha5, Ken Johnson6, Jinfu Hu7, Domenico Palli8, Monica Ferraroni1, Nuno Lunet9,10, Samantha Morais9,10, Shoichiro Tsugane11, Akihisa Hidaka11, Gerson Shigueaki Hamada12, Lizbeth López-Carrillo13, Raúl Ulises Hernández-Ramírez14, David Zaridze15, Dmitry Maximovitch15, Nuria Aragonés16,17, Vicente Martin16,18, Mary H Ward5, Jesus Vioque16,19, Manoli Garcia de la Hera16,19, Zuo-Feng Zhang20, Robert C Kurtz21, Pagona Lagiou22,23, Areti Lagiou24, Antonia Trichopoulou2, Anna Karakatsani2,25, Reza Malekzadeh26, M Constanza Camargo5, Maria Paula Curado27, Stefania Boccia28,29, Paolo Boffetta30,31, Eva Negri3, Carlo La Vecchia1. 1. Department of Clinical Sciences and Community Health, Branch of Medical Statistics, Biometry and Epidemiology "G.A. Maccacaro", University of Milan, Milan, Italy. 2. Hellenic Health Foundation, Athens, Greece. 3. Department of Biomedical and Clinical Sciences L. Sacco. 4. Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy. 5. Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA. 6. School of Epidemiology, Public Health and Preventive Medicine, University of Ottawa, Ottawa, Ontario, Canada. 7. Harbin Medical University, Harbin, China. 8. Cancer Risk Factors and Life-Style Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network, ISPRO, Florence, Italy. 9. EPIUnit - Instituto de Saúde Pública da Universidade do Porto. 10. Departamento de Ciências da Saúde Pública e Forenses e Educação Médica, Faculdade de Medicina da Universidade do Porto, Porto, Portugal. 11. Epidemiology and Prevention Group, Center for Public Health Sciences, National Cancer Center, Tokyo, Japan. 12. Nikkei Disease Prevention Center, São Paulo, Brazil. 13. Mexico National Institute of Public Health, Morelos, Mexico. 14. Department of Biostatistics, Yale School of Public Health, Yale School of Medicine, New Haven, Connecticut, USA. 15. Department of Epidemiology and Prevention, Russian N.N. Blokhin Cancer Research Center, Moscow, Russia. 16. Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP). 17. Cancer Epidemiology Section, Public Health Division, Department of Health of Madrid, Madrid. 18. Research Group in Gene-Environment Interactions and Health, University of León, León. 19. Nutritional Epidemiology Unit, Instituto de Investigación Sanitaria y Biomédica de Alicante, ISABIAL-UMH, Alicante, Spain. 20. Department of Epidemiology, UCLA Fielding School of Public Health and Jonsson Comprehensive Cancer Center, Los Angeles, California. 21. Department of Medicine, Memorial Sloan Kettering Cancer Centre, New York, New York, USA. 22. Department of Hygiene, Epidemiology and Medical Statistics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. 23. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA. 24. Department of Public and Community Health, School of Public Health, University of West Attica, Athens. 25. 2nd Pulmonary Medicine Department, National and Kapodistrian University of Athens, Medical School, "ATTIKON" University Hospital, Haidari, Greece. 26. Digestive Oncology Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran. 27. Centro Internacional de Pesquisa, A. C. Camargo Cancer Center, São Paulo, Brazil. 28. Section of Hygiene, University Department of Life Sciences and Public Health, Università Cattolica del Sacro Cuore. 29. Department of Woman and Child Health and Public Health - Public Health Area, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italia. 30. Stony Brook Cancer Center, Stony Brook University, Stony Brook, New York, USA. 31. Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
Abstract
OBJECTIVE: This study aimed to evaluate and quantify the relationship between coffee and gastric cancer using a uniquely large dataset from an international consortium of observational studies on gastric cancer, including data from 18 studies, for a total of 8198 cases and 21 419 controls. METHODS: A two-stage approach was used to obtain the pooled odds ratios (ORs) and the corresponding 95% confidence intervals (CIs) for coffee drinkers versus never or rare drinkers. A one-stage logistic mixed-effects model with a random intercept for each study was used to estimate the dose-response relationship. Estimates were adjusted for sex, age and the main recognized risk factors for gastric cancer. RESULTS: Compared to never or rare coffee drinkers, the estimated pooled OR for coffee drinkers was 1.03 (95% CI, 0.94-1.13). When the amount of coffee intake was considered, the pooled ORs were 0.91 (95% CI, 0.81-1.03) for drinkers of 1-2 cups per day, 0.95 (95% CI, 0.82-1.10) for 3-4 cups, and 0.95 (95% CI, 0.79-1.15) for five or more cups. An OR of 1.20 (95% CI, 0.91-1.58) was found for heavy coffee drinkers (seven or more cups of caffeinated coffee per day). A positive association emerged for high coffee intake (five or more cups per day) for gastric cardia cancer only. CONCLUSIONS: These findings better quantify the previously available evidence of the absence of a relevant association between coffee consumption and gastric cancer.
OBJECTIVE: This study aimed to evaluate and quantify the relationship between coffee and gastric cancer using a uniquely large dataset from an international consortium of observational studies on gastric cancer, including data from 18 studies, for a total of 8198 cases and 21 419 controls. METHODS: A two-stage approach was used to obtain the pooled odds ratios (ORs) and the corresponding 95% confidence intervals (CIs) for coffee drinkers versus never or rare drinkers. A one-stage logistic mixed-effects model with a random intercept for each study was used to estimate the dose-response relationship. Estimates were adjusted for sex, age and the main recognized risk factors for gastric cancer. RESULTS: Compared to never or rare coffee drinkers, the estimated pooled OR for coffee drinkers was 1.03 (95% CI, 0.94-1.13). When the amount of coffee intake was considered, the pooled ORs were 0.91 (95% CI, 0.81-1.03) for drinkers of 1-2 cups per day, 0.95 (95% CI, 0.82-1.10) for 3-4 cups, and 0.95 (95% CI, 0.79-1.15) for five or more cups. An OR of 1.20 (95% CI, 0.91-1.58) was found for heavy coffee drinkers (seven or more cups of caffeinated coffee per day). A positive association emerged for high coffee intake (five or more cups per day) for gastric cardia cancer only. CONCLUSIONS: These findings better quantify the previously available evidence of the absence of a relevant association between coffee consumption and gastric cancer.
Authors: Miguel Santibañez; Juan Alguacil; Manuela García de la Hera; Eva María Navarrete-Muñoz; Javier Llorca; Nuria Aragonés; Timo Kauppinen; Jesús Vioque Journal: Occup Environ Med Date: 2011-11-07 Impact factor: 4.402
Authors: E Buiatti; D Palli; A Decarli; D Amadori; C Avellini; S Bianchi; R Biserni; F Cipriani; P Cocco; A Giacosa Journal: Int J Cancer Date: 1989-10-15 Impact factor: 7.396
Authors: V Benetou; A Trichopoulou; P Orfanos; A Naska; P Lagiou; P Boffetta; D Trichopoulos Journal: Br J Cancer Date: 2008-07-08 Impact factor: 7.640
Authors: Evan Yi-Wen Yu; Anke Wesselius; Frits van Osch; Mariana Carla Stern; Xuejuan Jiang; Eliane Kellen; Chih-Ming Lu; Hermann Pohlabeln; Gunnar Steineck; James Marshall; Mohamed Farouk Allam; Carlo La Vecchia; Kenneth C Johnson; Simone Benhamou; Zuo-Feng Zhang; Cristina Bosetti; Jack A Taylor; Maurice P Zeegers Journal: Cancer Causes Control Date: 2019-05-30 Impact factor: 2.506